DDInter257 DDInter1628
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Butalbital {u} (Compound) resembles {v} (Compound) Butabarbital
Butabarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Butalbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Butalbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Butalbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Butalbital {u} (Compound) binds {v} (Gene) GABRA1
GABRA1 {u} (Gene) regulates {v} (Gene) DERA
DERA {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Butalbital {u} (Compound) binds {v} (Gene) GABRB3
GABRB3 {u} (Gene) regulates {v} (Gene) GABPB1
GABPB1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) MAP3K7
MAP3K7 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Butalbital (Compound) resembles Butabarbital (Compound) and Butabarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Ruxolitinib (Compound)
Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ruxolitinib (Compound)
Butalbital (Compound) binds GABRA1 (Gene) and GABRA1 (Gene) regulates DERA (Gene) and DERA (Gene) is downregulated by Ruxolitinib (Compound)
Butalbital (Compound) binds GABRB3 (Gene) and GABRB3 (Gene) regulates GABPB1 (Gene) and GABPB1 (Gene) is upregulated by Ruxolitinib (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) upregulates MAP3K7 (Gene) and MAP3K7 (Gene) is bound by Ruxolitinib (Compound)